In 2011, the American Cancer Society, the American Society for Colposcopy and Cervical
Pathology, and the American Society for Clinical Pathology updated screening guidelines …

Importance Cervical cancer can be prevented with detection and treatment of precancerous
cell changes caused primarily by high-risk types of human papillomavirus (hrHPV), the …

Several countries are in the process of switching to high-risk human papillomavirus (hrHPV)
testing for cervical cancer screening. Given the multitude of available tests, validated assays …

Importance Evidence is needed regarding the introduction of high-risk human
papillomavirus (hrHPV) testing into China's national cervical cancer screening program …

Cytology-based nation-wide cervical screening has led to a substantial reduction of the
incidence of cervical cancer in western countries. However, the sensitivity of cytology for the …

Background: High-risk human papillomavirus (hrHPV) testing has higher sensitivity but
lower specificity than cytology for cervical (pre)-cancerous lesions. Therefore, triage of …

Objectives ATHENA evaluated the cobas HPV Test as the primary screen for cervical cancer
in women≥ 25 years. This reports the 3-year end-of-study results comparing the …

Human papillomavirus (HPV) DNA testing was recently approved by the Food and Drug
Administration for use as an adjunct to cytology for cervical cancer screening. To help …

Cervical cancer screening involves a complex process of cytology, human papillomavirus
(HPV) testing, colposcopy, and a multitude of algorithms for the identification of preinvasive …

An update to the American Cancer Society (ACS) guideline regarding screening for the early
detection of cervical precancerous lesions and cancer is presented. The guidelines are …